Heron Therapeutics Q1 2025 net revenue $38.9M, record adj. EBITDA $6.2M, raises FY adj. EBITDA guidance to $4-12M

HERON THERAPEUTICS, INC. /DE/

2025-Q1 EPS reported $0.01 revenue$38,903,000

Net revenue of $38.9M, up 12.2% YoY; acute care franchise up 89.4% driven by ZYNRELEF (+60.4%).
Record Q1 adjusted EBITDA of $6.2M; full-year adj. EBITDA guidance raised to $4-12M from $0-8M.
Settled patent litigation with Mylan on CINVANTI/APONVIE; generic entry agreed for June 1, 2032.
Cash and investments $50.7M; ZYNRELEF prefilled syringe development on track for early 2027 launch.
NOPAIN Act took effect April 1; provides separate Medicare payment for non-opioids like ZYNRELEF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.